NP0332622 | Pepticinnamin N | | | C49H55N5O10
874.0040 Da 873.39489 Da | 1H NMR Spectrum (1D, 801 MHz, CD3OD, experimental) | [1H , 13C ]-HSQC NMR Spectrum (1D, 801 MHz, CD3OD, experimental) | [1H , 1H ]-COSY NMR Spectrum (1D, 801 MHz, CD3OD, experimental) | [1H , 13C ]-HMBC NMR Spectrum (1D, 801 MHz, CD3OD, experimental) | [1H , 13C ]-H2BC NMR Spectrum (1D, 801 MHz, CD3OD, experimental) | [1H , 1H ]-NOESY NMR Spectrum (1D, 801 MHz, CD3OD, experimental) |
|
NP0332614 | (3β, 6β)-urs-12-ene-3,6-diol | | | C30H50O2
442.7280 Da 442.38108 Da | 13C NMR Spectrum (1D, 151 MHz, CDCl3, experimental) | 1H NMR Spectrum (1D, 601 MHz, CDCl3, experimental) | [1H , 1H ]-COSY NMR Spectrum (1D, 601 MHz, CDCl3, experimental) | 13C NMR Spectrum (1D, 151 MHz, CDCl3, experimental) | 13C NMR Spectrum (1D, 151 MHz, CDCl3, experimental) | [1H , 13C ]-HMBC NMR Spectrum (1D, 601 MHz, CDCl3, experimental) | [1H , 13C ]-HSQC NMR Spectrum (1D, 601 MHz, CDCl3, experimental) | [1H , 1H ]-ROESY NMR Spectrum (1D, 601 MHz, CDCl3, experimental) |
|
NP0332613 | Noducyclamide B2 | | | C64H112N14O18
1365.6800 Da 1364.82790 Da | |
NP0332612 | Noducyclamide B1 | | | C64H112N14O19
1381.6790 Da 1380.82282 Da | |
NP0332611 | Noducyclamide A4 | | | C58H93N11O13
1152.4460 Da 1151.69543 Da | |
NP0332610 | Noducyclamide A3 | | | C58H93N11O14
1168.4450 Da 1167.69035 Da | |
NP0332609 | Noducyclamide A2 | | | C58H93N11O14
1168.4450 Da 1167.69035 Da | |
NP0332608 | Noducyclamide A1 | | | C58H93N11O15
1184.4440 Da 1183.68526 Da | |
NP0332607 | 3β-hydroxy-19-oxo-20,21-seco-29,30-nortaraxastan-21-oic acid | | | C28H46O4
446.6720 Da 446.33961 Da | 13C NMR Spectrum (1D, 126 MHz, C5D5N, simulated) | 1H NMR Spectrum (1D, 500 MHz, C5D5N, simulated) | 13C NMR Spectrum (1D, 126 MHz, C5D5N, experimental) | 1H NMR Spectrum (1D, 501 MHz, C5D5N, experimental) |
|
NP0332606 | 3β-hydroxy-19-oxo-20,21-seco-19-norlupan-21-oic acid | | | C27H44O4
432.6450 Da 432.32396 Da | 13C NMR Spectrum (1D, 126 MHz, C5D5N, simulated) | 1H NMR Spectrum (1D, 500 MHz, C5D5N, simulated) | 13C NMR Spectrum (1D, 126 MHz, C5D5N, experimental) | [1H , 1H ]-COSY NMR Spectrum (1D, 501 MHz, C5D5N, experimental) | 1H NMR Spectrum (1D, 501 MHz, C5D5N, experimental) | [1H , 13C ]-HMBC NMR Spectrum (1D, 501 MHz, C5D5N, experimental) | [1H , 13C ]-HSQC NMR Spectrum (1D, 501 MHz, C5D5N, experimental) | [1H , 1H ]-ROESY NMR Spectrum (1D, 501 MHz, C5D5N, experimental) |
|
NP0332605 | 3β-hydroxy-20-oxo-21,22-seco-30-nortaraxastan-22-oic acid | | | C29H48O4
460.6990 Da 460.35526 Da | 13C NMR Spectrum (1D, 126 MHz, C5D5N, simulated) | 1H NMR Spectrum (1D, 500 MHz, C5D5N, simulated) | 13C NMR Spectrum (1D, 126 MHz, C5D5N, experimental) | [1H , 1H ]-COSY NMR Spectrum (1D, 501 MHz, C5D5N, experimental) | 1H NMR Spectrum (1D, 501 MHz, C5D5N, experimental) | [1H , 13C ]-HMBC NMR Spectrum (1D, 501 MHz, C5D5N, experimental) | [1H , 13C ]-HSQC NMR Spectrum (1D, 501 MHz, C5D5N, experimental) | [1H , 1H ]-ROESY NMR Spectrum (1D, 501 MHz, C5D5N, experimental) |
|
NP0332603 | 3β-hydroxy-20,21-seco-30-nortaraxastan-20-oic-21-oate | | | C30H50O5
490.7250 Da 490.36582 Da | 13C NMR Spectrum (1D, 126 MHz, C5D5N, simulated) | 1H NMR Spectrum (1D, 500 MHz, C5D5N, simulated) | 13C NMR Spectrum (1D, 126 MHz, C5D5N, experimental) | 1H NMR Spectrum (1D, 501 MHz, C5D5N, experimental) | [1H , 13C ]-HMBC NMR Spectrum (1D, 501 MHz, C5D5N, experimental) | [1H , 13C ]-HSQC NMR Spectrum (1D, 501 MHz, C5D5N, experimental) | [1H , 1H ]-ROESY NMR Spectrum (1D, 501 MHz, C5D5N, experimental) |
|
NP0332602 | Acremoside G | | | C29H44O10
552.6610 Da 552.29345 Da | |
NP0332601 | Acremoside B | | | C30H48O10
568.7040 Da 568.32475 Da | |
NP0332600 | Acremoside C | | | C29H46O9
538.6780 Da 538.31418 Da | |
NP0332599 | Acremoside F | | | C30H46O10
566.6880 Da 566.30910 Da | |
NP0332598 | Acremoside A | | | C29H46O10
554.6770 Da 554.30910 Da | |
NP0332597 | Acremoside E | | | C29H44O10
552.6610 Da 552.29345 Da | |
NP0332596 | Acremoside D | | | C28H44O9
524.6510 Da 524.29853 Da | |
NP0332595 | Compound 9 | | | C24H32O8
448.5120 Da 448.20972 Da | |
NP0332594 | Compound 12b | | | C33H38O10
594.6570 Da 594.24650 Da | 1H NMR Spectrum (1D, 500 MHz, CDCl3, simulated) | 1H NMR Spectrum (1D, 501 MHz, CDCl3, experimental) | [1H , 1H ]-COSY NMR Spectrum (1D, 501 MHz, CDCl3, experimental) |
|
NP0332593 | Compound 8 | | | C30H34O8
522.5940 Da 522.22537 Da | 1H NMR Spectrum (1D, 600 MHz, CDCl3, simulated) | 13C NMR Spectrum (1D, 151 MHz, CDCl3, simulated) | 1H NMR Spectrum (1D, 601 MHz, CDCl3, experimental) | 13C NMR Spectrum (1D, 151 MHz, CDCl3, experimental) |
|
NP0332592 | Compound 12a | | | C33H38O10
594.6570 Da 594.24650 Da | 1H NMR Spectrum (1D, 500 MHz, CDCl3, simulated) | 1H NMR Spectrum (1D, 501 MHz, CDCl3, experimental) | [1H , 1H ]-COSY NMR Spectrum (1D, 501 MHz, CDCl3, experimental) |
|
NP0332591 | Kavaratamide A | | | C32H55N3O8
609.8050 Da 609.39892 Da | [1H , 1H ]-COSY NMR Spectrum (1D, 501 MHz, CDCL3, experimental) | 13C NMR Spectrum (1D, 126 MHz, CDCL3, experimental) | [1H , 13C ]-HMBC NMR Spectrum (1D, 126 MHz, CDCL3, experimental) | [1H , 1H ]-NOESY NMR Spectrum (1D, 501 MHz, CDCL3, experimental) | 1H NMR Spectrum (1D, 501 MHz, CDCL3, experimental) |
|
NP0332590 | 5’-O-desmethylarmillaribin | | | C23H26O5
382.4560 Da 382.17802 Da | 13C NMR Spectrum (1D, 126 MHz, C3D6O, simulated) | 1H NMR Spectrum (1D, 500 MHz, C3D6O, simulated) | 13C NMR Spectrum (1D, 126 MHz, C3D6O, experimental) | 1H NMR Spectrum (1D, 501 MHz, C3D6O, experimental) | [1H , 13C ]-HMBC NMR Spectrum (1D, 501 MHz, C3D6O, experimental) | [1H , 13C ]-HSQC NMR Spectrum (1D, 501 MHz, C3D6O, experimental) | [1H , 1H ]-ROESY NMR Spectrum (1D, 501 MHz, C3D6O, experimental) | [1H , 1H ]-COSY NMR Spectrum (1D, 501 MHz, C2D6OS, experimental) |
|